Revelation Biosciences Q3 2026: $9.1M Cash, Going Concern, Nasdaq MVLS Delisting Risk
REVB sits 16% above its 52-week low of $3.08.
Summary
Revelation Biosciences posted a $9.6 million nine-month net loss and held $9.1 million of cash, warned it cannot fund a full year of operations, and flagged that its listed-securities value sits below the $5 million threshold of a new Nasdaq automatic-delisting rule.
Key Events · Earnings and Guidance · REVB
-
Q3 2026 Loss Widens to $9.6M
Nine-month net loss reached $9.6 million versus $6.4 million a year earlier, with Q3 alone losing $3.3 million as R&D rose to $1.5 million from $0.9 million.
-
Cash Falls to $9.1M, Going Concern
Cash and equivalents dropped to $9.1 million from $10.7 million at December 31, 2025, and management says the balance will not sustain operations for a year.
-
Nasdaq MVLS Delisting Risk
Under a new Nasdaq rule, companies whose listed-securities value stays below $5 million for 30 consecutive business days face automatic delisting with no cure period; the company says it is currently below that level.
-
Reverse Split Resets Warrant Strikes
The October 20, 2026 1-for-7 split cut Class C, D, G, H, I and J warrant exercise prices from $12.46 to $3.29 and raised Class G warrant shares from 489,250 to 1,852,908.
Analysis · REVB · Life Sciences
A fresh capital raise is now on the near-term agenda: the company closed September 30, 2026 with $9.1 million in cash against a $9.6 million nine-month net loss, and management states plainly that this balance will not fund operations for a year. Layered on top is a newly operative Nasdaq rule that automatically delists companies whose listed-securities value stays under $5 million for 30 consecutive business days, with no cure period; the filing says the company is already below that threshold. Even after the 1-for-7 reverse split on October 20, 2026, the equity structure remains heavily overhung — that split reset warrant strikes from $12.46 to $3.29 and ballooned Class G warrant shares to 1,852,908.
How filings like this one have moved
In the 30 days to Nov 5, 2026, 43.4% of the 1274 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.16%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, REVB was trading at $3.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $3.08 to $40.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.